Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof

US2019233456A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2019233456-A1
Application numberUS-201716337338-A
CountryUS
Kind codeA1
Filing dateSep 19, 2017
Priority dateSep 29, 2016
Publication dateAug 1, 2019
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw material, (S)-β3-amino acid is obtained by asymmetric resolution induced by using a nickel chelate, and Maraviroc is synthesized by using (S)-3-amino-3-phenylpropionic acid as a key intermediate with a high yield and the ee value reaching 98.2% or more. The method of the present invention has widely available materials, mild synthetic process conditions, is easy to control, and produces a product of a high optical purity.

First claim

Opening claim text (preview).

1 . A synthesis method for a novel quaternary carbon chiral ligand, wherein the synthesis method comprises the step of synthesizing a compound of formula VI, wherein n is an integer from 1 to 4; R is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 1 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 2 is selected from the group consisting of H, halogen, amino, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 3 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl, unsubstituted or substituted phenyl and —(C1-C4 alkylene)-(unsubstituted or substituted phenyl); wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl. 2 . A novel resolution method for an alpha amino acid, an alpha substituted beta amino acid and a beta substituted beta amino acid comprising the step of hydrolyzing a compound of formula VI to obtain the alpha amino acid, the alpha substituted beta amino acid and the beta substituted beta amino acid of formula VII, wherein n is an integer from 1 to 4, m is an integer from 0 to 1; R is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 1 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 2 is selected from the group consisting of H, halogen, amino, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 3 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl, unsubstituted or substituted phenyl and —(C1-C4 alkylene)-(unsubstituted or substituted phenyl); wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl; R 4 is selected from the group consisting of H, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted C3-C6 heteroaryl and unsubstituted or substituted C3-C6 cycloalkyl, wherein the “substituted” means that there are 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, nitro, cyano, C1-C4 alkyl, C1-C4 alkoxy and C1-C4 haloalkyl; R 5 is selected from the group consisting of H, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted C3-C6 heteroaryl and unsubstituted or substituted C3-C6 cycloalkyl, wherein the “substituted” means that there are 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, nitro, cyano, C1-C4 alkyl, C1-C4 alkoxy and C1-C4 haloalkyl. 3 . The resolution method of claim 2 , wherein the compound of VI is synthesized by the following step: reacting a compound of formula IV with an unnatural amino acid of formula V under the action of a nickel salt to form the compound of formula VI, wherein n, m, R, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 2 . 4 . A Maravino intermediate having a structure of formula VI: wherein n, m, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 2 . 5 . A novel chiral ligand having a structure of formula Y: wherein n, R, R 1 , R 2 and R 3 are as defined in claim 2 . 6 . A method for synthesizing Maraviro comprising the step of synthesizing a Maraviro intermediate, wherein the Maraviro intermediate is: the step of synthesizing the Maraviro intermediate is as defined in claim 2 , wherein n, R 1 , R 2 and R 3 are as defined in claim 2 and R 4 is phenyl. 7 . A method for synthesizing an unnatural amino acid comprising the following steps: (i) reacting (R)-2-substituted proline with di-tert-butyl dicarbonate to form (R)-1-(tert-butoxycarbonyl)-2-methylproline; (ii) subjecting (R)-1-(tert-butoxycarbonyl)-2-substituted proline to a condensation reaction with a compound of formula I to obtain a compound of formula II; (iii) removing tert-butoxycarbonyl from the compound of formula II to obtain a compound of formula III; (iv) subjecting the compound of formula III to a reductive amination reaction with R 3 CHO or R 3 CH 2 Cl to obtain a compound of formula IV; (v) reacting the compound of formula IV with various unnatural amino acids of formula V under the action of a nickel salt to form a compound of VI; (vi) hydrolyzing the compound of VI to form a compound of VII, wherein n, m, R, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 2 . 8 . A method for synthesizing a key intermediate of Maraviro, wherein the key intermediate of Maraviro is: the synthesis method includes the following steps: (i) reacting the compound IV with 3-amino-3-phenylpropionic acid under the action of a nickel salt to obtain a compound of formula VI′; (ii) hydrolyzing the compound of formula VI′ to obtain a compound of formula VII, wherein n, R, R 1 , R 2 and R 3 are as defined in claim 1 . 9 . A method for synthesizing Maraviro comprising the step of synthesizing a key intermediate of Maraviro, wherein the key intermediate of Maraviro is: the step of synthesizing the key intermediate of Maraviro is as defined in claim 8 . 10 . A method for synthesizing Maraviro, wherein the method further comprises the following steps: (i) reacting (S)-β 3 -phenylalanine with di-tert-butyl dicarbonate to obtain a compound of formula VIII;

Assignees

Inventors

Classifications

  • C07D207/16Primary

    Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

  • by separation of optical isomers · CPC title

  • the carbon skeleton containing six-membered aromatic rings · CPC title

  • linked by a chain containing hetero atoms as chain links · CPC title

  • with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2019233456A1 cover?
Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw material, (S)-β3-amino acid is obtained by asymmetric resolution induced by using a nickel chelate, and Maraviroc is synthesized by using (S)-3-amino-3-phenylpr…
Who is the assignee on this patent?
Shanghai Inst Materia Medica Cas
What technology area does this patent fall under?
Primary CPC classification C07D207/16. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Aug 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).